Mario David Saltarelli
Directeur/Membre du Conseil chez BIOASIS TECHNOLOGIES INC.
Fortune : - $ au 31/05/2024
Postes actifs de Mario David Saltarelli
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BIOASIS TECHNOLOGIES INC. | Directeur/Membre du Conseil | 30/05/2019 | - |
GABA Therapeutics, Inc.
 GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | Directeur Général | 04/04/2022 | - |
| Directeur Technique/Scientifique/R&D | 04/04/2022 | - |
Historique de carrière de Mario David Saltarelli
Anciens postes connus de Mario David Saltarelli
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| US Green Valley Pharmaceuticals, Inc. | Directeur Général | 01/11/2020 | 01/06/2021 |
Neuron23, Inc.
 Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Directeur Général | 01/06/2020 | 01/10/2020 |
| ENTRADA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 19/03/2019 | 01/06/2020 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Directeur Technique/Scientifique/R&D | 01/01/2018 | 01/11/2018 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/01/2017 | 01/07/2018 |
| MALLINCKRODT PLC | Directeur Technique/Scientifique/R&D | 24/10/2013 | 01/06/2015 |
| SHIRE | Directeur Technique/Scientifique/R&D | 08/02/2011 | 01/09/2013 |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░░ ░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░░░ ░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
Formation de Mario David Saltarelli
| University of Illinois | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 16 |
| Irlande | 3 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 7 |
| Corporate Officer/Principal | 4 |
| Chief Executive Officer | 3 |
Sectorielle
| Health Technology | 13 |
| Consumer Services | 4 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| PFIZER, INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| ANNEXON, INC. | Health Technology |
| MALLINCKRODT PLC | Health Technology |
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| ENTRADA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
Mallinckrodt Brand Pharmaceuticals LLC
 Mallinckrodt Brand Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Mallinckrodt Brand Pharmaceuticals, Inc. engages in the manufacture of pharmaceutical and health products. The company was founded on September 23, 2015 and is headquartered in Hazelwood, MO. | Health Technology |
Mindimmune Therapeutics, Inc.
 Mindimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mindimmune Therapeutics, Inc. develops drugs that target the immune system to treat diseases of the central nervous system. It focuses on the treatment of Alzheimer's, Huntington's disease, pain, and psychiatric disorders. The company was founded by Stevin Zorn, Frank S. Menniti, Robert B. Nelson, and Brian M. Campbell on July 12, 2016 and is headquartered in Kingston, RI. | Health Technology |
GABA Therapeutics, Inc.
GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | Health Technology |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Commercial Services |
| US Green Valley Pharmaceuticals, Inc. |
- Bourse
- Insiders
- Mario David Saltarelli
- Expérience
